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ABSTRACT 
Many countries have introduced policies that enable patients to select a health care 
provider of their choice with the aim of improving the quality of care. However, there is 
little information about the drivers or the impact of patient mobility. Using 
administrative hospital data (n=19,256) we analysed the mobility of prostate cancer 
patients who had 
radical surgery in England between 2010 and 2014. Our analysis, using geographic 
information systems and multivariable choice modelling, found that 33·5% (n= 6,465) of 
men bypassed their nearest prostate cancer surgical centre. Travel time had a strong 
impact on where patients moved to but was less of a factor for men who were younger, 
fitter, and more affluent (p always <0·001). Men were more likely to move to hospitals 
that provided robotic prostate cancer surgery (odds ratio 1·42, p<0·001) and to hospitals 
that employed surgeons with a strong media reputation (odds ratio 2·18, p<0·001). 
Patient mobility occurred in the absence of validated measures of the quality of care, 
instead influenced by 
46 the adoption of robotic surgery and the reputation of individual clinicians. National 
policy 
based on patient choice and provider competition may have had a negative impact on 
equality of access, service capacity, and health system efficiency. 
 
Patient summary 
In this study we assessed the reasons why men would choose to have prostate cancer 
surgery at a centre other than their nearest. We found that in England men were 
attracted to centres that carried out robotic surgery and employed surgeons with a 
national reputation. 
 
Many high-income countries have introduced policies that 55 aim to improve the quality 
of care by stimulating competition between hospital providers and allowing patients to 
choose the hospital where they have treatment.1 In publicly funded health care markets 
such as the UK, funding follows the patient, creating quite powerful incentives for 
hospitals to attract new patients by demonstrating superior quality.2 
To date, our understanding of the extent and determinants of patient mobility across 
health services remains limited, due to a paucity of available research and heterogeneity 
in the design of empirical studies.3 The aim of the present study is to undertake the first-
ever national analysis assessing the impact of choice and competition policies within 
cancer care. 
 
Our aim was to investigate whether prostate cancer patients, who had a radical 
prostateĐtoŵǇ ;RPͿ iŶ the EŶglish NH“, traǀelled ďeǇoŶd ;͞ďǇpassed͟Ϳ their Ŷearest 
hospital, and the hospital and patient characteristics associated with that mobility. 
We obtained individual patient-level data on all men (n=19, 256) who were diagnosed 
with prostate cancer and underwent RP in the English NHS between 1st January 2010 and 
31st December 2014 from the National Cancer Registration and Analysis Service (NCRAS) 
and linked at patient level to Hospital Episode Statistics (HES). Patient characteristics of 
the study cohort are presented in Supplementary Table 1. 
 
The populatioŶ ǁeighted ĐeŶtroids of the patieŶts’ Loǁer “uper Output Areas 
(geographic areas defined by the Office for National Statistics that typically includes 
1,500 residents or 650 households) and the full postcodes for the hospitals where the 77 
surgery was undertaken were inputted into a geographical information system (ESRI 
ArcGIS 10.3) to calculate travel times according to the fastest route by car (using 
Ordnance Survey MasterMap Integrated Transport Network). For each patient, the 
travel time to all prostate cancer surgical centres  (n=65) was calculated. The proportion 
of patients not receiving care at their nearest centre ǁere ĐoŶsidered to ďe ͞ďǇpassers͟. 
We determined three hospital-level characteristics. These were informed by a 
systematic review of the literature and qualitative interviews with both men previously 
treated for prostate cancer and uro-oncology specialists currently practicing in the UK. 
We labelled the 12 hospitals that carried out robotic prostatectomies at the start of the 
studǇ period as ͞estaďlished roďotiĐ ĐeŶtres͟. We ideŶtified the ϯϭ ͞uŶiǀersity teaching 
hospitals͟, ďased oŶ their ŵeŵďership of the AssoĐiatioŶ of UK UŶiǀersitǇ Hospitals. We 
also defiŶed the ϭϮ hospitals ǁith a ͞stroŶg ŵedia reputatioŶ͟, ďased oŶ ǁhether or Ŷot 
theǇ eŵploǇed urologists that ǁere listed iŶ ϮϬϭϬ as the ͞ďest͟ prostate cancer 
surgeons in the UK ďǇ the ͞DailǇ Mail͟,4 which is the only nationally published source 
recognising expert prostate cancer surgeons. Further details on selection of hospital 
characteristics is available in the supplemental content. 
 
Conditional logit regression was used to model the odds that a patient moved to a 
particular hospital as a function of travel time and hospital and patient characteristics.5 
For each patient, we created a data set that included for each patient a row for each 
hospital providing prostate cancer surgery at the time of treatment (number of hospitals 
varied between 57 and 65 as eight hospitals closed during the study p 101 eriod). The 
dependent variable of the conditional logit model was a dummy variable with a value of 
1 for the hospital where a patient had his treatment and a value of 0 otherwise. Patient 
characteristics were included as interaction terms with travel time in the model and 
included age, number of comorbidities, socioeconomic status (based on national 
quintiles of the Index of Multiple Deprivation)6,and urban or rural residence.7 Further 
detail on patient characteristics and the statistical methods is available in the 
supplemental content. 
 
Our aŶalǇsis deŵoŶstrated that ϲ,ϰϲϱ ŵeŶ ;ϯϯ·ϱ%Ϳ ͞ďǇpassed͟ the nearest centre that 
carried out prostate cancer surgery. 2386 men (12·4%) bypassed at least three hospitals 
for their treatment and 1,258 men (6·5%) at least five hospitals (Supplementary Table 2). 
There were clear differences in bypass rates between the nine English regions. In 
London, 50·9% of men had their prostate cancer surgery at the nearest centre whilst 
corresponding percentages were 86·5% in the North East and 80·6% in Yorkshire and 
Humberside (Supplementary Table 3). 
 
Travel time had a strong impact on the odds that a patient chose a particular hospital to 
receive surgery. The odds of a patient choosing a hospital that was up to 10 minutes 
further aǁaǇ thaŶ the patieŶt’s Ŷearest hospital that Đarried out prostate ĐaŶĐer surgerǇ 
was found to be on average 78% smaller (OR of 0.22). The odds decreased markedly as 
the additional travel time increased (Table 1). 
 
The addition of patient characteristics as interaction terms into our model demonstrated 
that the impact of travel time was smaller for men who were younger, for those who 
were fitter (no recorded comorbidities), and for those who lived in more affluent or rural 
areas ;odds ratios larger thaŶ ͞ϭ͟ ;Taďle ϭͿͿ. For eǆaŵple, agaiŶ Đoŵpared to haǀiŶg the 
surgery at the nearest hospital, for men in rural areas, the likelihood of moving to a 
hospital that was up to 10 minutes further away was estimated to be 2·5 times smaller 
(= 1 / (0·22 x 1·79)) whereas the corresponding figure for men from urban areas is 4.8 (= 
1 / 0·22). 
 
Patients were 1·42 times more likely to move to one of the 12 hospitals that were 
established robotic centres compared to those that were not and 2·18 times more likely 
to move to the 12 hospitals that employed surgeons who had a strong media reputation 
(Table 1). University teaching hospital status had a small but statistically significant 
impact (OR 1·09, p<0·001) on attracting patients. 
 
These findings have a number of policy implications that are relevant across a range of 
elective secondary care services in countries that have introduced patient choice of 
provider policies.3 A substantial number of patients, well above the 5% to 10% thought 
to be necessary to incentivise improvements in quality,8 were prepared to move to 
hospitals further away for radical prostatectomy. This occurred in the absence of 
evidence that these hospitals achieved better outcomes. Instead, they responded to the 
availability of more advanced surgical technology and the perceived reputation of the 
hospitals’ surgeoŶs. 
 
The provision of robotic surgery has been noted to attract patients 145 to providers in 
health care markets across Europe and North America,9 resulting in a rapid growth in the 
number of providers offering this technology. Our own data supports this: men were 
more likely to choose one of the 12 established robotic centres in the NHS. It is likely 
that this competitive advantage has contributed to the large-scale investment in 
equipment for robotic surgery across the NHS.10 There has been a more than threefold 
increase in the number of centres offering this modality between 2010 and 2016 (from 
12 to 42 centres). 
 
Hospital and clinician reputation have also been identified in other studies as important 
factors influencing decision making for cancer surgery.11 This suggests that patients, with 
or without guidance from their primary care physician, social and medical networks or 
clinician who diagnosed the cancer, respond to indicators that in their view reflect 
differences in treatment quality.12 
 
The list of prostate cancer surgeons with a national reputation was compiled by the 
Daily Mail following a survey of urologists working in the UK. Much of the intelligence is 
therefore likely to be representative of the discussions that are ongoing within particular 
regions both amongst clinicians as well as patient and carer support groups. It can 
therefore be considered as a proxy for the wider reputation of hospitals. 
 
The patterns of mobility observed in England has resulted in large and unexpected shifts 
in market share for hospitals carrying out prostate cancer surgery. For some hospitals, 
nearly 80% of patients for whom that hospital was the nearest 167 provider chose to 
have their treatment elsewhere. Conversely, other hospitals were performing up to 
200% more operations than expected because patients from elsewhere travelled to 
these hospitals for their surgery. Such extremes of mobility are likely to have a negative 
impact on health system efficiency (due to lengthening waiting lists for some and 
unused capacity for others) with some surgical units facing the threat of closure given 
that funding is contingent on the number of procedures performed.2,10 Equally, surgical 
unit closures and the greater regionalization that results may serve to improve 
efficiency. 
 
Our modelling of patient mobility had a number of limitations. First, we used 
administrative dataset and it is likely that we have missed less severe comorbid 
conditions. Second, the study used centroids of small geographical areas to represent 
the location of the patieŶts’ resideŶĐe. This ǁill haǀe added ͞Ŷoise͟ to the 
determination of travel times. 
 
In conclusion, men are willing to travel for prostate cancer surgery, especially those that 
are relatively young, fit and affluent. The study highlights that without appropriate 
quality iŶforŵatioŶ to guide patieŶts’ ĐhoiĐes, patieŶts are iŶflueŶĐed ďǇ the reputatioŶ 
of hospitals and their surgeons and the availability of innovative technologies. National 
policy based on patient choice and provider competition may have a negative impact on 
service capacity, equality of access, and health system efficiency. 
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